Zura Bio Limited (NASDAQ:ZURA) Receives $18.00 Consensus Target Price from Analysts

Zura Bio Limited (NASDAQ:ZURA) has received an average recommendation of “Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $18.00.

Several equities research analysts recently issued reports on the stock. Piper Sandler began coverage on shares of Zura Bio in a report on Friday. They issued an “overweight” rating and a $26.00 target price for the company. Oppenheimer reissued an “outperform” rating and issued a $16.00 price target (down from $17.00) on shares of Zura Bio in a research report on Monday, April 1st.

Zura Bio Stock Performance

Shares of ZURA stock opened at $4.62 on Friday. Zura Bio has a 12-month low of $2.00 and a 12-month high of $14.00. The firm’s 50 day moving average is $3.26 and its 200 day moving average is $3.93.

Insider Activity at Zura Bio

In related news, Director Amit Munshi purchased 159,744 shares of Zura Bio stock in a transaction dated Monday, April 22nd. The shares were acquired at an average cost of $3.13 per share, with a total value of $499,998.72. Following the purchase, the director now owns 777,384 shares of the company’s stock, valued at $2,433,211.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders purchased 170,926 shares of company stock valued at $534,998. 15.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Forefront Analytics LLC raised its stake in Zura Bio by 46.8% during the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock worth $99,000 after acquiring an additional 6,765 shares in the last quarter. Raymond James & Associates grew its position in Zura Bio by 14.0% during the 3rd quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after purchasing an additional 9,481 shares during the last quarter. Lynx1 Capital Management LP purchased a new stake in shares of Zura Bio in the third quarter valued at about $65,000. Bank of New York Mellon Corp acquired a new stake in shares of Zura Bio during the third quarter worth about $224,000. Finally, Eisler Capital US LLC acquired a new position in Zura Bio in the 3rd quarter valued at about $660,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.